Overview

Thalidomide for Multiple Myeloma

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The objective of this protocol is to assess therapeutic activity of thalidomide in previously untreated patients with asymptomatic multiple myeloma.
Phase:
Phase 3
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Celgene Corporation
Treatments:
Thalidomide